.svg)
Highlighted Event
Results for the First Quarter 2024
Sales ended at MNOK 133.8, 3.5% above the first quarter last year (MNOK 129.3). Currency neutral sales of own products was down 1%. Recurring sales remain high at 75% or MNOK 83.5 (68% or MNOK 73.8) for the quarter.
Results for the First Quarter 2023
Apr 25, 2023
NOK 82.1. The Vascular business segment continues the positive development and grows at 21.5% in NOK, currency neutral 8.8% growth. The Imaging products grow at 9.4% in NOK, currency neutral decline of 3.7%. Currency neutral…
Medistim is opening a direct sales office in China
Apr 3, 2023
More than 60,000 coronary bypass procedures are performed in China annually and the number is expected to continue to grow high single digit in the years to come. Today, about 70% of these procedures are…
Annual Report 2022
Mar 31, 2023
Further supported by several high-quality symposia at the largest heart surgery conferences, we achieved 44 % growth in the imaging product portfolio in 2022. And while steadily penetrating the Cardiac bypass market, we also build…
Medistim Expands Market Coverage in Canada by Going Direct
Mar 22, 2023
“We are excited to announce this strategic move that will strengthen our relationship with our customers in Canada and grow our business there,” – Medistim President and CEO Kari E. Krogstad
Results for the Fourth Quarter and Preliminary Results for 2022
Mar 1, 2023
All major geographical regions drive sales growth. Currency-neutral sales increased by 21.6 % for the quarter and 11.9 % for the year. Currency-neutral sales of own products increase 24.6 % for the quarter and 14.0…
Capital Markets Day
Feb 27, 2023
See the recording from Medistim's Capital Markets Day on March 21st where two international thought leaders, Professors John. D. Puskas and Pirkka Vikatmaa shared their insights on the future trends in Cardiac and Vascular Surgery…
